Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835
Books209
All textbooksMedical textbooksHuman anatomyOrganisms & biodiversityOther sciences
Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›OROS-methylphenidate to reduce ADHD symptoms in male prisoners aged 16–25 years: a RCT›References

Continue where you left off ()

GO BEYOND THE PAGEReading is just the beginning.

Turn scientific reading into research. Compare studies, examine evidence, and organize your findings in EvidenceHelix Workspace.

Explore Research Workspace →

OROS-methylphenidate to reduce ADHD symptoms in male prisoners aged 16–25 years: a RCT · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 14 min read

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013. 10.1176/appi.books.9780890425596
  2. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother 2005;5:525–39. 10.1586/14737175.5.4.52516026236
  3. Asherson P, Buitelaar J, Faraone SV, Rohde LA. Adult attention-deficit hyperactivity disorder: key conceptual issues. Lancet Psychiatry 2016;3:568–78. 10.1016/S2215-0366(16)30032-327183901
  4. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry 2010;10:67. 10.1186/1471-244X-10-6720815868
  5. Kooij JJS, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, et al. Updated European consensus statement on diagnosis and treatment of adult ADHD. Eur Psychiatry 2019;56:14–34. 10.1016/j.eurpsy.2018.11.00130453134
  6. Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Romos-Quiroga JA, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers 2015;1:15020. 10.1038/nrdp.2015.2027189265
  7. Fayyad J, Sampson NA, Hwang I, Adamowski T, Aguilar-Gaxiola S, Al-Hamzawi A, et al. The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys. Atten Defic Hyperact Disord 2017;9:47–65. 10.1007/s12402-016-0208-327866355
  8. Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry 2007;20:386–92. 10.1097/YCO.0b013e3281568d7a17551354
  9. Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 2014;43:434–42. 10.1093/ije/dyt26124464188
  10. Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402–9. 10.1192/bjp.bp.106.03438917470954
  11. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009;194:204–11. 10.1192/bjp.bp.107.04882719252145
  12. Young S, Moss D, Sedgwick O, Fridman M, Hodgkins P. A meta-analysis of the prevalence of attention deficit hyperactivity disorder in incarcerated populations. Psychol Med 2015;45:247–58. 10.1017/S003329171400076225066071
  13. National Institute for Health and Care Excellence (NICE). Attention Deficit Hyperactivity Disorder: Diagnosis and Management. Clinical Guideline [CG72]. London: NICE; 2008.
  14. National Institute for Health and Care Excellence (NICE). Attention Deficit Hyperactivity Disorder: Diagnosis and Management. NICE Guideline [NG87]. London: NICE; 2018.
  15. Scottish Intercollegiate Guidelines Network. Management of Attention Deficit Hyperactivity and Hyperkinetic Disorders in Children and Young People: A National Clinical Guideline. Edinburgh: SIGN; 2009.
  16. Lenzi F, Cortese S, Harris J, Masi G. Pharmacotherapy of emotional dysregulation in adults with ADHD: a systematic review and meta-analysis. Neurosci Biobehav Rev 2018;84:359–67. 10.1016/j.neubiorev.2017.08.01028837827
  17. Moukhtarian TR, Cooper RE, Vassos E, Moran P, Asherson P. Effects of stimulants and atomoxetine on emotional lability in adults: a systematic review and meta-analysis. Eur Psychiatry 2017;44:198–207. 10.1016/j.eurpsy.2017.05.02128646732
  18. Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 2013;170:275–89. 10.1176/appi.ajp.2012.1207099123360949
  19. Daley D, Van Der Oord S, Ferrin M, Cortese S, Danckaerts M, Doepfner M, et al. Practitioner review: current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder. J Child Psychol Psychiatry 2018;59:932–47. 10.1111/jcpp.1282529083042
  20. Retz W, Rösler M, Ose C, Scherag A, Alm B, Philipsen A, et al. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate. World J Biol Psychiatry 2012;13:48–59. 10.3109/15622975.2010.54025721155632
  21. Young S, Gudjonsson G, Chitsabesan P, Colley B, Farrag E, Forrester A, et al. Identification and treatment of offenders with attention-deficit/hyperactivity disorder in the prison population: a practical approach based upon expert consensus. BMC Psychiatry 2018;18:281. 10.1186/s12888-018-1858-930180832
  22. Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry 2018;5:824–35. 10.1016/S2215-0366(18)30293-130220514
  23. National Institute for Health and Care Excellence (NICE). Attention Deficit Hyperactivity Disorder: Evidence Update 45. 2013. URL: http://arms.evidence.nhs.uk/resources/hub/1027558/attachment (accessed November 2020).
  24. Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2009;23:733–44. 10.1177/026988110809233818562416
  25. Cunill R, Castells X, Tobias A, Capellà D. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. J Psychopharmacol 2015;29:15–23. 10.1177/026988111454477725142405
  26. Crunelle CL, van den Brink W, Moggi F, Konstenius M, Franck J, Levin FR, et al. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. Eur Addict Res 2018;24:43–51. 10.1159/00048776729510390
  27. Skoglund C, Brandt L, Almqvist C, D’Onofrio BM, Konstenius M, Franck J, Larsson H. Factors associated with adherence to methylphenidate treatment in adult patients with attention-deficit/hyperactivity disorder and substance use disorders. J Clin Psychopharmacol 2016;36:222–8. 10.1097/JCP.000000000000050127043119
  28. Skoglund C, Brandt L, D’Onofrio B, Larsson H, Franck J. Methylphenidate doses in attention deficit/hyperactivity disorder and comorbid substance use disorders. Eur Neuropsychopharmacol 2017;27:1144–52. 10.1016/j.euroneuro.2017.08.43528935267
  29. Asherson P, Evans C, Young S. A Pilot Study of Concerta XL in Adult Offenders with ADHD. 2018. URL: www.clinicaltrialsregister.eu/ctr-search/trial/2012-000517-37/results (accessed 18 January 2021).
  30. Barkley R, Murphy K. A Clinical Workbook: Attention-Deficit Hyperactivity Disorder. 3rd edn. New York, NY: Guilford; 1998. 10.1038/scientificamerican0998-66
  31. Kooij JJ. Diagnostic Interview for ADHD in Adults 2.0 (DIVA 2.0). In Kooij JJ, editor. Diagnostic Assessment and Treatment. Amsterdam: Pearson Assessment and Information BV; 2010.
  32. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018;5:727–38. 10.1016/S2215-0366(18)30269-430097390
  33. Ginsberg Y, Lindefors N. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension. Br J Psychiatry 2012;200:68–73. 10.1192/bjp.bp.111.09294022075648
  34. Chang Z, Ghirardi L, Quinn PD, Asherson P, D’Onofrio BM, Larsson H. Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry 2019;86:335–43. 10.1016/j.biopsych.2019.04.00931155139
  35. Chen Q, Sjölander A, Runeson B, D’Onofrio BM, Lichtenstein P, Larsson H. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 2014;348:g3769. 10.1136/bmj.g376924942388
  36. Chang Z, Lichtenstein P, D’Onofrio BM, Sjölander A, Larsson H. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry 2014;71:319–25. 10.1001/jamapsychiatry.2013.417424477798
  37. Chang Z, D’Onofrio BM, Quinn PD, Lichtenstein P, Larsson H. Medication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. Biol Psychiatry 2016;80:916–22. 10.1016/j.biopsych.2016.02.01827086545
  38. Quinn PD, Chang Z, Hur K, Gibbons RD, Lahey B, Rickert ME, et al. ADHD medication and substance-related problems. Am J Psychiatry 2017;174:877–85. 10.1176/appi.ajp.2017.1606068628659039
  39. Chang Z, Lichtenstein P, Halldner L, D’Onofrio B, Serlachius E, Fazel S, et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry 2014;55:878–85. 10.1111/jcpp.1216425158998
  40. Viktorin A, Rydén E, Thase ME, Chang Z, Lundholm C, D’Onofrio BM, et al. The risk of treatment-emergent mania with methylphenidate in bipolar disorder. Am J Psychiatry 2017;174:341–8. 10.1176/appi.ajp.2016.1604046727690517
  41. Hollis C, Chen Q, Chang Z, Quinn PD, Viktorin A, Lichtenstein P, et al. Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. Lancet Psychiatry 2019;6:651–8. 10.1016/S2215-0366(19)30189-031221557
  42. Lichtenstein P, Larsson H. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2013;368:776. 10.1056/NEJMc1215531
  43. Chang Z, Lichtenstein P, Långström N, Larsson H, Fazel S. Association between prescription of major psychotropic medications and violent reoffending after prison release. JAMA 2016;316:1798–807. 10.1001/jama.2016.1538027802545
  44. Young S, Gudjonsson GH, Wells J, Asherson P, Theobald D, Oliver B, et al. Attention deficit hyperactivity disorder and critical incidents in a Scottish prison population. Pers Individ Differ 2009;46:265–9. 10.1016/j.paid.2008.10.003
  45. Skirrow C, McLoughlin G, Kuntsi J, Asherson P. Behavioral, neurocognitive and treatment overlap between attention-deficit/hyperactivity disorder and mood instability. Expert Rev Neurother 2009;9:489–503. 10.1586/ern.09.219344301
  46. Moukhtarian TR. Investigation in the Overlap of ADHD and Borderline Personality Disorder: A Multi-modal Approach. PhD thesis. London: King’s College London; 2019.
  47. Kockler TD, Santangelo PS, Limberger MF, Bohus M, Ebner-Priemer UW. Specific or transdiagnostic? The occurrence of emotions and their association with distress in the daily life of patients with borderline personality disorder compared to clinical and healthy controls. Psychiatry Res 2020;284:112692. 10.1016/j.psychres.2019.11269231784065
  48. Kockler TD, Tschacher W, Santangelo PS, Limberger MF, Ebner-Priemer UW. Specificity of emotion sequences in borderline personality disorder compared to posttraumatic stress disorder, bulimia nervosa, and healthy controls: an e-diary study. Borderline Personal Disord Emot Dysregul 2017;4:26. 10.1186/s40479-017-0077-129276606
  49. Young SJ, Adamou M, Bolea B, Gudjonsson G, Müller U, Pitts M, et al. The identification and management of ADHD offenders within the criminal justice system: a consensus statement from the UK Adult ADHD Network and criminal justice agencies. BMC Psychiatry 2011;11:32. 10.1186/1471-244X-11-3221332994
  50. Swanson JM, Volkow ND. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev 2003;27:615–21. 10.1016/j.neubiorev.2003.08.01314624806
  51. Faraone SV, Hess J, Wilens T. Prevalence and Consequences of the nonmedical use of amphetamine among persons calling poison control centers. J Atten Disord 2019;23:1219–28. 10.1177/108705471984318231169052
  52. Asherson P, Johansson L, Holland R, Fahy T, Forester A, Howitt S, et al. Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention-deficit/hyperactivity disorder (CIAO-II). Trials 2019;20:663. 10.1186/s13063-019-3705-931791384
  53. Wilding IR, Clark D, Wray H, Alderman J, Muirhead N, Sikes CR. In vivo disintegration profiles of encapsulated and nonencapsulated sumatriptan: gamma scintigraphy in healthy volunteers. J Clin Pharmacol 2005;45:101–5. 10.1177/009127000427056015601811
  54. Faust MB. Effect of variations in backfill on dissolution for an overencapsulated comparator product. Pharm Eng 1999;19:48–54.
  55. Esseku F, Lesher M, Bijlani V, Adeyeye MC. Overencapsulation and Drug Product Performance of Selected Drugs using Hard Gelatin DBcaps Capsules. American Association of Pharmaceutical Scientists Annual Meeting, Baltimore, MD, 2004.
  56. Electronic Medicines Compendium. Concerta XL 18 mg Prolonged-release Tablets. URL: www.medicines.org.uk/emc/product/6872/smpc (accessed 21 January 2021).
  57. European Medicines Agency. Good Manufacturing Practice. URL: www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice (accessed 21 January 2021).
  58. Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S. Randomized, double-blind, placebo-controlled acute comparator trials of lisdexamfetamine and extended-release methylphenidate in adolescents with attention-deficit/hyperactivity disorder. CNS Drugs 2017;31:999–1014. 10.1007/s40263-017-0468-228980198
  59. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006;59:829–35. 10.1016/j.biopsych.2005.09.01116373066
  60. Joint Formulary Committee. British National Formulary. 62nd edn. London: BMJ Group and Pharmaceutical Press; 2011.
  61. Asherson P, Johansson L, Holland R, Bedding M, Forrester A, Giannulli L, et al. Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study [published online ahead of print June 3 2022]. Br J Psychiatry 2022. 10.1192/bjp.2022.77
  62. Black DW, Arndt S, Hale N, Rogerson R. Use of the Mini International Neuropsychiatric Interview (MINI) as a screening tool in prisons: results of a preliminary study. J Am Acad Psychiatry Law 2004;32:158–62.15281417
  63. Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL, Frankenburg FR, Hennen J. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord 2003;17:233–42. 10.1521/pedi.17.3.233.2214712839102
  64. Conners CK, Erhardt D, Sparrow E. Adult ADHD Rating Scales (CAARS). Technical Manual. New York, NY: Multi Health Systems Inc.; 1999.
  65. Reimherr FW, Marchant BK, Strong RE, Hedges DW, Adler L, Spencer TJ, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry 2005;58:125–31. 10.1016/j.biopsych.2005.04.04016038683
  66. Rösler M, Retz W, Fischer R, Ose C, Alm B, Deckert J, et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry 2010;11:709–18. 10.3109/1562297100362419720353312
  67. Canadian ADHD Resource Alliance. CADDRA Patient ADHD Medication Form. URL: www.caddra.ca/wp-content/uploads/CADDRA-Patient-ADHD-Medication-Form.pdf (accessed 2015).
  68. Guy W. Clinical Global Impressions (CGI) Scale, Modified. In Rush JA, editor. Task Force for the Handbook of Psychiatric Measures Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000.
  69. Raine A, Dodge K, Loeber R, Gatzke-Kopp L, Lynam D, Reynolds C, et al. The Reactive–Proactive Aggression Questionnaire: differential correlates of reactive and proactive aggression in adolescent boys. Aggress Behav 2006;32:159–71. 10.1002/ab.2011520798781
  70. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998;158:1789–95. 10.1001/archinte.158.16.17899738608
  71. Saitz R, Palfai TP, Cheng DM, Alford DP, Bernstein JA, Lloyd-Travaglini CA, et al. Screening and brief intervention for drug use in primary care: the ASPIRE randomized clinical trial. JAMA 2014;312:502–13. 10.1001/jama.2014.786225096690
  72. Bernstein DP, Stein JA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl 2003;27:169–90. 10.1016/S0145-2134(02)00541-012615092
  73. Stringaris A, Goodman R, Ferdinando S, Razdan V, Muhrer E, Leibenluft E, Brotman MA. The Affective Reactivity Index: a concise irritability scale for clinical and research settings. J Child Psychol Psychiatry 2012;53:1109–17. 10.1111/j.1469-7610.2012.02561.x22574736
  74. Mowlem FD, Skirrow C, Reid P, Maltezos S, Nijjar SK, Merwood A, et al. Validation of the Mind Excessively Wandering Scale and the relationship of mind wandering to impairment in adult ADHD. J Atten Disord 2016. 10.1177/1087054716651927
  75. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med 1983;13:595–605. 10.1017/S00332917000480176622612
  76. Walker J, Bowes N. The evaluation of violent thinking in adult offenders and non-offenders using the Maudsley Violence Questionnaire. Crim Behav Ment Health 2013;23:113–23. 10.1002/cbm.186123595862
  77. Evans C, Connell J, Barkham M, Margison F, McGrath G, Mellor-Clark J, Audin K. Towards a standardised brief outcome measure: psychometric properties and utility of the CORE-OM. Br J Psychiatry 2002;180:51–60. 10.1192/bjp.180.1.5111772852
  78. Knoedler DW. The Modified Overt Aggression Scale. Am J Psychiatry 1989;146:1081–2. 10.1176/ajp.146.8.1081b
  79. Wright J. Classroom Behaviour Report Card Resource Book. 2003. URL: www.interventioncentral.org (accessed 18 January 2021).
  80. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175–91. 10.3758/BF0319314617695343
  81. Imai K, Keele L, Tingley D. A general approach to causal mediation analysis. Psychol Methods 2010;15:309–34. 10.1037/a002076120954780
  82. The Scottish Government. Preventing Offending: Getting it Right for Children and Young People. Edinburgh: The Scottish Government; 2015.
  83. Great Britain. The Medicines for Human Use (Clinical Trials) Regulations 2004. London: The Stationery Office; 2004.
  84. Great Britain. The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006. London: The Stationery Office; 2006.
  85. Medical Research Council. MRC Clinical Trials Series: MRC Guidelines for Good Clinical Practice in Clinical Trials. URL: https://mrc.ukri.org/documents/pdf/good-clinical-practice-in-clinical-trials/ (accessed 4 February 2021).
  86. World Medical Association. Declaration of Helsinki 1996. URL: www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/doh-oct1996/ (accessed 4 February 2021).
  87. Good Clinical Practice Network. ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice ICH E6(R2) ICH Consensus Guideline. URL: https://ichgcp.net/# (accessed 4 February 2021).
  88. Great Britain. Data Protection Act 1998. London: The Stationery Office; 1998.
  89. Independent Monitoring Boards. Report of the Independent Monitoring Board: January–December 2013. URL: www.imb.org.uk/app/uploads/2015/01/isis-2013.pdf (accessed 18 January 2021).
  90. Singleton N, Meltzer H, Gatward R, Coid J, Deasy D. Psychiatric Morbidity Among Prisoners in England and Wales. Newport: Office for National Statistics; 1998. 10.1037/e591872010-001
  91. Lichtenstein P, Halldner L, Zetterqvist J, Sjölander A, Serlachius E, Fazel S, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012;367:2006–14. 10.1056/NEJMoa120324123171097
  92. Office for National Statistics. 2011 Census. Who We Are. How We Live. What We Do. URL: https://webarchive.nationalarchives.gov.uk/20160129062745/http://www.ons.gov.uk/ons/guide-method/census/2011/index.html (accessed 4 February 2021).
  93. Uhrig N. Black, Asian and Minority Ethnic Disproportionality in the Criminal Justice System in England and Wales. London: Ministry of Justice; 2016.
  94. Fazel S, Seewald K. Severe mental illness in 33,588 prisoners worldwide: systematic review and meta-regression analysis. Br J Psychiatry 2012;200:364–73. 10.1192/bjp.bp.111.09637022550330
  95. Konstenius M, Jayaram-Lindström N, Guterstam J, Beck O, Philips B, Franck J. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction 2014;109:440–9. 10.1111/add.1236924118269
  96. HM Inspectorate of Prisons. Changing Patterns of Substance Misuse in Adult Prisons and Service Responses. London: HM Inspectorate of Prisons; 2015.
  97. Moukhtarian TR, Mintah RS, Moran P, Asherson P. Emotion dysregulation in attention-deficit/hyperactivity disorder and borderline personality disorder. Borderline Personal Disord Emot Dysregul 2018;5:9. 10.1186/s40479-018-0086-829796281
  98. Brown NM, Brown SN, Briggs RD, Germán M, Belamarich PF, Oyeku SO. Associations between adverse childhood experiences and ADHD diagnosis and severity. Acad Pediatr 2017;17:349–55. 10.1016/j.acap.2016.08.01328477799
  99. Forneris CA, Gartlehner G, Brownley KA, Gaynes BN, Sonis J, Coker-Schwimmer E, et al. Interventions to prevent post-traumatic stress disorder: a systematic review. Am J Prev Med 2013;44:635–50. 10.1016/j.amepre.2013.02.01323683982
  100. Szymanski K, Sapanski L, Conway F. Trauma and ADHD — association or diagnostic confusion? A clinical perspective. J Infant Child Adolesc Psychother 2011;10:51–9. 10.1080/15289168.2011.575704
  101. Shiroma EJ, Ferguson PL, Pickelsimer EE. Prevalence of traumatic brain injury in an offender population: a meta-analysis. J Correct Health Care 2010;16:147–59. 10.1177/107834580935653820339132
  102. Young S, González RA, Fridman M, Hodgkins P, Kim K, Gudjonsson GH. Health-related quality of life in prisoners with attention-deficit hyperactivity disorder and head injury. BMC Psychiatry 2018;18:209. 10.1186/s12888-018-1785-929929487
  103. Chitsabesan P, Lennox C, Williams H, Tariq O, Shaw J. Traumatic brain injury in juvenile offenders: findings from the comprehensive health assessment tool study and the development of a specialist linkworker service. J Head Trauma Rehabil 2015;30:106–15. 10.1097/HTR.000000000000012925734841
  104. Huang CH, Huang CC, Sun CK, Lin GH, Hou WH. Methylphenidate on cognitive improvement in patients with traumatic brain injury: a meta-analysis. Curr Neuropharmacol 2016;14:272–81. 10.2174/1570159X1366615051423303326951094
  105. Philipsen A, Jans T, Graf E, Matthies S, Borel P, Colla M, et al. Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry 2015;72:1199–210. 10.1001/jamapsychiatry.2015.214626536057
  106. Krumpal I. Determinants of social desirability bias in sensitive surveys: a literature review. Qual Quant 2013;47:2025–47. 10.1007/s11135-011-9640-9
  107. Morberg BM, Malling AS, Jensen BR, Gredal O, Wermuth L, Bech P. The Hawthorne effect as a pre-placebo expectation in Parkinsons disease patients participating in a randomized placebo-controlled clinical study. Nord J Psychiatry 2018;72:442–6. 10.1080/08039488.2018.146848030744517
  108. Piper M, Forrester A, Shaw J. Prison healthcare services: the need for political courage. Br J Psychiatry 2019:215:579–81. 10.1192/bjp.2019.43
  109. Ismail N. The politics of austerity, imprisonment and ignorance: a case study of English prisons. Med Sci Law 2020;60:89–92. 10.1177/002580241989974432041476
  110. House of Commons Justice Select Committee. Prisons: Planning and Policies. London: Justice Select Committee; 2015.
  111. HM Chief Inspector of Prisons. Report on an Unannounced Inspection of HMP/YOI Isis: 17–28 February 2014. URL: www.justiceinspectorates.gov.uk/hmiprisons/wp-content/uploads/sites/4/2014/08/Isis-Web-2014.pdf (accessed 4 February 2021).
  112. HM Chief Inspector of Prisons. Report on an Unannounced Inspection of HMP/YOI Isis: 23 July–2 August 2018. URL: www.justiceinspectorates.gov.uk/hmiprisons/wp-content/uploads/sites/4/2018/12/HMP-YOI-Isis-Web-2018.pdf (accessed 4 February 2021).
  113. Sadlier G. Evaluation of the Impact of the HM Prison Service Enhanced Thinking Skills Programme on Reoffending Outcomes of the Surveying Prisoner Crime Reduction (SPCR) Sample. London; Ministry of Justice; 2010.
  114. Till A, Forrester A, Exworthy T. The development of equivalence as a mechanism to improve prison healthcare. J R Soc Med 2014;107:179–82. 10.1177/014107681452394924566935
  115. Goodwin N, Lawton-Smith S. Integrating care for people with mental illness: the Care Programme Approach in England and its implications for long-term conditions management. Int J Integr Care 2010;10:e040. 10.5334/ijic.51625035692
← Discussion (including interpretation, generalisability, overall evidence)Acknowledgements →

Attribution. Philip Asherson; Lena Johansson; Rachel Holland; Megan Bedding; Andrew Forrester; Laura Giannulli et al. (2022). OROS-methylphenidate to reduce ADHD symptoms in male prisoners aged 16–25 years: a RCT. National Institute for Health and Care Research. Copyright © 2022 Asherson et al. This work was produced by Asherson et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited. Licensed under CC BY 4.0. NCBI Bookshelf NBK581759. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support